Frontiers in Immunology · 2019 · 36 citations · 61 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingMolecular ImagingPulmonologyInterstitial Lung DiseaseInterstitial Lung Disease ImagingPulmonary ImagingPulmonary InflammationPulmonary Nuclear ImagingActivated Macrophage ImagingBiodistribution StudiesFibrotic Interstitial Lung DiseaseInterstitial Lung Disease DetectionLung FibrosisPulmonary Macrophage ActivationRadiotracer Uptake QuantificationRadiotracers Targeting Macrophages
Background Interstitial lung disease (ILD) is a common and severe complication in rheumatic diseases. Folate receptor-β is expressed on activated, but not resting macrophages which play a key role in dysregulated tissue repair including ILD. We therefore aimed to pre-clinically evaluate the potential of 18F-AzaFol-based PET/CT (positron emission computed tomography/computed tomography) for the specific detection of macrophage-driven pathophysiologic processes in experimental ILD. Methods The pulmonary expression of folate receptor-β was analysed in patients with different subtypes of ILD as well as in bleomycin (BLM)-treated mice and respective controls using immunohistochemistry. PET/CT was performed at days 3, 7, and 14 after BLM instillation using the 18F-based folate radiotracer 18F-AzaFol. The specific pulmonary accumulation of the radiotracer was assessed by ex vivo PET/CT scans and quantified by ex vivo biodistribution studies. Results Folate receptor-β expression was 3- to 4-fold increased in patients with fibrotic ILD, including idiopathic pulmonary fibrosis and connective tissue disease-related ILD, and significantly correlated with the degree of lung remodelling. A similar increase in the expression of folate receptor-β was observed in experimental lung fibrosis, where it also correlated with disease extent. In the mouse model of BLM-induced ILD, pulmonary accumulation of 18F-AzaFol reflected macrophage-related disease development with good correlation of folate receptor-β positivity with radiotracer uptake. In the ex vivo imaging and biodistribution studies, the maximum lung accumulation was observed at day 7 with a mean accumulation of 1.01 ± 0.30% injected activity/lung in BLM-treated versus control animals (0.31 ± 0.06% % injected activity/lung; p<0.01). Conclusion Our preclinical proof-of-concept study demonstrated the potential of 18F-AzaFol as a novel imaging tool for the visualisation of macrophage-driven fibrotic lung diseases.
61
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine · 2019 · 1.6K citations · Full text